Dr Saptarshi Mukherjee


Journal Articles

  1. & Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia. The Journal of Physiology 594(21), 6431-6432.
  2. & Unambiguous observation of blocked states reveals altered, blocker-induced, cardiac ryanodine receptor gating. Scientific Reports 6(1)
  3. & Structural insights into Ca2+-activated long-range allosteric channel gating of RyR1. Cell Research 26(9), 977-994.
  4. & The Mechanism of Flecainide Action in CPVT Does Not Involve a Direct Effect on RyR2. Circulation Research 116(8), 1324-1335.
  5. & Insights into the Gating Mechanism of the Ryanodine-Modified Human Cardiac Ca2+-Release Channel (Ryanodine Receptor 2). Molecular Pharmacology 86(3), 318-329.
  6. & N-terminus oligomerization regulates the function of cardiac ryanodine receptors. Journal of Cell Science 126(21), 5042-5051.
  7. & A mechanistic description of gating of the human cardiac ryanodine receptor in a regulated minimal environment. The Journal of General Physiology 140(2), 139-158.
  8. & Ryanodine receptor mutations in arrhythmia: The continuing mystery of channel dysfunction. FEBS Letters 584(10), 2153-2160.

Book Chapters

  1. & Cochrane Database of Systematic Reviews. In